Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Christiane Smerling"'
Autor:
Lukas Greifenstein, Annika Gunkel, Aileen Hoehne, Frank Osterkamp, Christiane Smerling, Christian Landvogt, Corinna Mueller, Richard P. Baum
Publikováno v:
iScience, Vol 26, Iss 12, Pp 108541- (2023)
Summary: Hardly any new tracers attracted more attention in nuclear medicine in the last couple of years than radiolabeled fibroblast activation protein inhibitors (FAPi’s). Molecules targeting cancer-associated fibroblasts (CAFs) or disease-associ
Externí odkaz:
https://doaj.org/article/8ff7f2035d1c4fc78234a014be25587e
Autor:
Dirk Zboralski, Aileen Hoehne, Anne Bredenbeck, Anne Schumann, Minh Nguyen, Eberhard Schneider, Jan Ungewiss, Matthias Paschke, Christian Haase, Jan L. von Hacht, Tanya Kwan, Kevin K. Lin, Jan Lenore, Thomas C. Harding, Jim Xiao, Andrew D. Simmons, Ajay-Mohan Mohan, Nicola Beindorff, Ulrich Reineke, Christiane Smerling, Frank Osterkamp
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 49:3651-3667
Purpose Fibroblast activation protein (FAP) is a membrane-bound protease that has limited expression in normal adult tissues but is highly expressed in the tumor microenvironment of many solid cancers. FAP-2286 is a FAP-binding peptide coupled to a r
Autor:
Frankis Almaguel, Franz C Robiller, Aviral Singh, Dirk Mueller, Christiane Smerling, Maythinee Chantadisai, Aleksandr Eismant, Christiane Schuchardt, Jingjing Zhang, Frank Osterkamp, Aileen Hoehne, Dirk Zboralski, Ulrich Reineke, Richard P. Baum, Harshad R. Kulkarni
Publikováno v:
Journal of Nuclear Medicine. 63:415-423
Fibroblast activation protein (FAP) is a promising target for diagnosis and therapy of numerous malignant tumors. FAP-2286 is the conjugate of a FAP-binding peptide, which can be labeled with radionuclides for theranostic applications. We present the
Autor:
Richard P, Baum, Christiane, Schuchardt, Aviral, Singh, Maythinee, Chantadisai, Franz C, Robiller, Jingjing, Zhang, Dirk, Mueller, Alexander, Eismant, Frankis, Almaguel, Dirk, Zboralski, Frank, Osterkamp, Aileen, Hoehne, Ulrich, Reineke, Christiane, Smerling, Harshad R, Kulkarni
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 63(3)
Fibroblast activation protein (FAP) is a promising target for diagnosis and therapy of numerous malignant tumors. FAP-2286 is the conjugate of a FAP-binding peptide, which can be labeled with radionuclides for theranostic applications. We present the
Autor:
Tanya T. Kwan, Minh Nguyen, Dirk Zboralski, Anne Schumann, Anne Bredenbeck, Matthias Paschke, Christian Haase, Aileen Hoehne, Ulrich Reineke, Christiane Smerling, Frank Osterkamp, Jim Xiao, Andrew D. Simmons, Thomas C. Harding, Kevin L. Lin
Publikováno v:
Molecular Cancer Therapeutics. 20:LBA032-LBA032
Background: FAP is a membrane-bound protease with limited expression in normal tissues but high expression on cancer-associated fibroblasts abundant in the stroma of most tumors. FAP-2286 is a potent and selective FAP-targeted peptide linked to the c
Autor:
Christiane Smerling, Ulrich Reineke, Christiane Schuchardt, Aviral Singh, Harshad R. Kulkarni, Richard P. Baum, Stefan Wiessalla, Frank Osterkamp, Ingo Klette
Publikováno v:
Journal of Nuclear Medicine. 59:809-814
Neurotensin receptor 1 (NTR1) is overexpressed in ductal pancreatic adenocarcinoma, which is still one of the deadliest cancers, with a very poor prognosis. Eligible patients were offered salvage radiopharmaceutical therapy with the novel NTR1 antago
Autor:
Martin Rohracker, Christiane Smerling, Holger Amthauer, Aileen Höhne, Jürgen Goldschmidt, Anette Pethe, Mercedes Noriega, Ulrich Reineke, Marvin Stiebler, Jörg Schulz, Frank Osterkamp, Mathias Lukas, Franziska Stöber
Publikováno v:
Journal of Nuclear Medicine. 58:936-941
Increased expression of neurotensin receptor 1 (NTR1) has been shown in a large number of tumor entities such as pancreatic or colon carcinoma. Hence, this receptor is a promising target for diagnostic imaging and radioligand therapy. Using the favor
Autor:
Christiane Smerling, Ulrich Reineke, Marvin Stiebler, Annette Pethe, Jörg Schulz, Frank Osterkamp, Holger Amthauer, Oliver S. Grosser, Jürgen Goldschmidt, Martin Rohracker
Publikováno v:
Journal of Nuclear Medicine. 57:1120-1123
Neurotensin receptor-1 (NTR1) is a promising target for diagnostic imaging and targeted radionuclide therapy. The aim of this study was to evaluate the biodistribution profiles of a series of newly developed diarylpyrazole-based NTR1 antagonists rega
Autor:
Christiane Smerling, Luigi Del Pozzo, Eleni Gourni, Emilie Kheirallah, Beatrice Waser, Philipp T. Meyer, Brett M. Paterson, Helmut R. Maecke, Paul S. Donnelly, Jean Claude Reubi
Publikováno v:
Molecular Pharmaceutics. 12:2781-2790
The gastrin-releasing peptide receptor (GRPr) is an important molecular target for the visualization and therapy of tumors and can be targeted with radiolabeled bombesin derivatives. The present study aims to develop statine-based bombesin receptor a
Autor:
Jörg, Schulz, Martin, Rohracker, Marvin, Stiebler, Jürgen, Goldschmidt, Franziska, Stöber, Mercedes, Noriega, Anette, Pethe, Mathias, Lukas, Frank, Osterkamp, Ulrich, Reineke, Aileen, Höhne, Christiane, Smerling, Holger, Amthauer
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 58(6)
Increased expression of neurotensin receptor 1 (NTR1) has been shown in a large number of tumor entities such as pancreatic or colon carcinoma. Hence, this receptor is a promising target for diagnostic imaging and radioligand therapy. Using the favor